miR-155 releases the brakes on antitumor T cells

Homeostatic γC cytokines are essential to support the expansion and function of tumor-specific T cells, but their effects are constrained by suppressor of cytokine signaling (SOCS) proteins as well as phosphoinositide and tyrosine-specific phosphatases. The microRNA miR-155 counteracts these inhibitory hurdles to potentiate intracellular cytokine signaling and T cell antitumor immunity.

[1]  T. Waldmann,et al.  miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines , 2014, Proceedings of the National Academy of Sciences.

[2]  P. Romero,et al.  MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. , 2013, Immunity.

[3]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[4]  E. Celis,et al.  A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. , 2012, Cancer research.

[5]  G. Trinchieri,et al.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. , 2010, Cancer research.

[6]  Ryan M. O’Connell,et al.  Inositol phosphatase SHIP1 is a primary target of miR-155 , 2009, Proceedings of the National Academy of Sciences.

[7]  S. Rosenberg,et al.  Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? , 2006, Nature Clinical Practice Oncology.

[8]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[9]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[10]  A Sasaki,et al.  Negative regulation of cytokine signaling pathways. , 2000, Annual review of immunology.